His primary scientific interests are in Internal medicine, Adverse effect, Randomized controlled trial, Intensive care medicine and Meta-analysis. His Internal medicine research incorporates themes from Antibiotics, Antibacterial agent and Surgery. His Adverse effect research includes themes of Placebo, Discontinuation, Typhoid fever and Breast cancer.
The various areas that he examines in his Randomized controlled trial study include Clinical trial, Community-acquired pneumonia, Colistin, Physical therapy and Pneumococcal pneumonia. His Intensive care medicine research incorporates elements of Observational study, Medical prescription, Combination therapy and Drug. The study incorporates disciplines such as Endocrinology, Quality of life, Immunology, Pharmacotherapy and Dose-dense chemotherapy in addition to Meta-analysis.
Leonard Leibovici focuses on Internal medicine, Intensive care medicine, Antibiotics, Randomized controlled trial and Surgery. Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Bacteremia. His Intensive care medicine research is multidisciplinary, incorporating elements of Clinical trial, Febrile neutropenia, Neutropenia, Decision support system and Combination therapy.
In Antibiotics, Leonard Leibovici works on issues like Pediatrics, which are connected to Epidemiology. As a member of one scientific family, Leonard Leibovici mostly works in the field of Randomized controlled trial, focusing on Colistin and, on occasion, Meropenem. His Adverse effect study integrates concerns from other disciplines, such as Placebo and Discontinuation.
His main research concerns Internal medicine, Randomized controlled trial, Odds ratio, Retrospective cohort study and Colistin. His is doing research in Urinary system, Confidence interval, Mortality rate, Cohort and Adverse effect, both of which are found in Internal medicine. His work deals with themes such as Relative risk, Discontinuation, Emergency medicine and Patient experience, which intersect with Adverse effect.
His studies deal with areas such as Observational study, Meta-analysis, Subgroup analysis, Combination therapy and Polymyxin as well as Randomized controlled trial. His Odds ratio research is multidisciplinary, incorporating elements of Multivariate analysis and Antibiotics. His Antibiotics study combines topics from a wide range of disciplines, such as Medical microbiology, Pseudomonas aeruginosa and Intensive care medicine.
Leonard Leibovici mostly deals with Internal medicine, Adverse effect, Antibiotics, Randomized controlled trial and Mortality rate. His studies in Odds ratio, Urinary system, Meta-analysis, Interquartile range and Pneumonia are all subfields of Internal medicine research. His study looks at the relationship between Meta-analysis and topics such as Relative risk, which overlap with Cochrane Library and Secondary infection.
Leonard Leibovici interconnects Clinical trial, Discontinuation and Confidence interval in the investigation of issues within Adverse effect. His research in Antibiotics tackles topics such as Pseudomonas aeruginosa which are related to areas like Bacilli, Microbiology and Drug. In his study, which falls under the umbrella issue of Antibiotic resistance, Intensive care medicine is strongly linked to Carbapenem-resistant enterobacteriaceae.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Evelina Tacconelli;Elena Carrara;Alessia Savoldi;Stephan Harbarth.
Lancet Infectious Diseases (2017)
The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
Leibovici L;Shraga I;Drucker M;Konigsberger H.
Journal of Internal Medicine (1998)
Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis
Mical Paul;Vered Shani;Eli Muchtar;Galia Kariv.
Antimicrobial Agents and Chemotherapy (2010)
β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials
Mical Paul;Ishay Benuri-Silbiger;Karla Soares-Weiser;Leonard Leibovici.
Meta-analysis : Antibiotic prophylaxis reduces mortality in neutropenic patients
Anat Gafter-Gvili;Abigail Fraser;Mical Paul;Leonard Leibovici.
Annals of Internal Medicine (2005)
Seronegative Lyme Disease
David A. Relman;Gideon Nesher;Thomas G. Osborn;Terry L. Moore.
The New England Journal of Medicine (1988)
Beta lactam antibiotic monotherapy versus beta lactam‐aminoglycoside antibiotic combination therapy for sepsis
Mical Paul;Adi Lador;Simona Grozinsky-Glasberg;Leonard Leibovici.
Cochrane Database of Systematic Reviews (2014)
Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
Anat Stern;Hefziba Green;Mical Paul;Liat Vidal.
Cochrane Database of Systematic Reviews (2014)
Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals
Matthieu Million;Emmanouil Angelakis;Mical Paul;Fabrice Armougom.
Microbial Pathogenesis (2012)
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy
Anat Gafter-Gvili;Abigail Fraser;Mical Paul;Liat Vidal.
Cochrane Database of Systematic Reviews (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: